Citigroup
RCKT icon

Citigroup’s Rocket Pharmaceuticals RCKT Stock Holding History

Citigroup’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-59,900
Closed -$400K – 5860
2025
Q1 		$400K Buy
+59,900
New +$592K ﹤0.01% 3800

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup's RCKT Position: Q2 2026 in Review

Citigroup reduced its Rocket Pharmaceuticals (RCKT) stake by 4.7% in Q2 2026, selling an estimated $805K and leaving 4,865,551 shares worth $16.6M. The position accounts for 0.01% of the portfolio, ranked #1274.

Citigroup first reported a position in RCKT in Q1 2015 and has held it in 40 quarters since. The position peaked at $18.4M in Q4 2025. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Citigroup held 4,865,551 shares of Rocket Pharmaceuticals worth $16.6M as of Q2 2026.
  • Citigroup sold 242,157 Rocket Pharmaceuticals shares in Q2 2026, an estimated $805K.
  • Rocket Pharmaceuticals made up 0.01% of Citigroup's portfolio in Q2 2026, its #1274 holding.
  • Citigroup first reported a position in Rocket Pharmaceuticals in Q1 2015 and has held it in 40 quarters since.
  • Citigroup's Rocket Pharmaceuticals position peaked at $18.4M in Q4 2025.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.